References
- Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382(9904):1575-86
- Nunes EA, MacKenzie EM, Rossolatos D, et al. D-serine and schizophrenia: an update. Expert Rev Neurother 2012;12:801-12
- Kinch MS, Patridge E. An analysis of FDA-approved drugs for psychiatric disorders. Drug Discov Today 2014; Available from: http://dx.doi.org/10.1016/
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-15
- Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 2013;11:126. Available from: www.biomedcentral.com/1741-7015/11/126
- Counts SE, Lahiri DK. Editorial: overview of immunotherapy in Alzeimer’s Disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. Curr Alzheimer Res 2014;11:623-5
- Alzheimer’s Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer’s Disease anti-inflammatory prevention trial (ADAPT). Alzheimers Dement 2013;9:714-23
- Imbimbo BP, Giardina GA. γ-secretase inhibitors and modulators for the treatment of Alzheimer’s Disease: disappointments and hopes. Curr Top Med Chem 2011;11:1555-70
- Clinical trials funding opportunity announcements. Available from: www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/index.shtml
- Borges S, Chen YF, Laughren TP, et al. Review of maintenance trials for major depression disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry 2014;75:205-14